

The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books

Feb 25, 2020 • 59min
Ep63: Jeremy Levin
Jeremy Levin, chairman of BIO, on the perilous moment in politics.

Feb 11, 2020 • 56min
Ep62: Jane Grogan
Jane Grogan, CSO of Arsenal Bio, on programmable cell therapies.

Jan 27, 2020 • 1h 5min
Ep61: Sanjiv Patel
Sanjiv Patel, CEO of Relay Therapeutics, computational drug discovery company.

Jan 14, 2020 • 1h 10min
Ep60: Tim Mayleben
Tim Mayleben, CEO of Esperion Therapeutics, on cholesterol-lowering meds.

Dec 30, 2019 • 1h 2min
Ep59: David Baker
David Baker, University of Washington protein designer.

Dec 3, 2019 • 1h 12min
Ep58: Jigar Raythatha
Jigar Raythatha of Constellation Pharma on epigenetic drug development.

Nov 26, 2019 • 1h 21min
Ep57: John Alam
John Alam on Alzheimer's drug development.

Nov 13, 2019 • 1h 5min
Ep56: Tim Springer
Tim Springer of Harvard Medical School on his career in science and biotech.

Oct 29, 2019 • 1h 7min
Ep55: John Hawkins & Jim Geraghty
Discussion on the new Henri Termeer biography.

Oct 15, 2019 • 1h 6min
Ep54: Aoife Brennan
CEO of Synlogic on developing synthetic biology-based drugs.